Who are Pioglitazone Plus dapaglifliozin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pioglitazone-plus-dapaglifliozin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Pioglitazone Plus dapaglifliozin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pioglitazone Plus dapaglifliozin (Pioglitazone Plus dapaglifliozin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT2 inhibitor and thiazolidinedione. Area: Diabetes.

phase 3 SGLT2 inhibitor and thiazolidinedione PPAR-γ and SGLT2 Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Pioglitazone Plus dapaglifliozin (Pioglitazone Plus dapaglifliozin) — Hamad Medical Corporation. Pioglitazone is a thiazolidinedione that activates PPAR-γ, increasing insulin sensitivity, while dapagliflozin is an SGLT2 inhibitor that reduces glucose reabsorption in the kidneys.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pioglitazone Plus dapaglifliozin TARGET	Pioglitazone Plus dapaglifliozin	Hamad Medical Corporation	phase 3	SGLT2 inhibitor and thiazolidinedione	PPAR-γ and SGLT2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT2 inhibitor and thiazolidinedione class)

Hamad Medical Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pioglitazone Plus dapaglifliozin — Competitive Intelligence Brief. https://druglandscape.com/ci/pioglitazone-plus-dapaglifliozin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab